This post was originally published on this site In a recent study, a team of researchers found a new compound that can be administered as eye drops and partly reversed cataracts in a mice model. The study, “Pharmacological chaperone for α-crystallin partially restores transparency in cataract models,” was published in the journal Science. Cataracts are the most common cause of…
This post was originally published on this site Hispanic-American patients with Alzheimer’s disease tend to live significantly longer after disease onset and with milder cognitive decline than African-Americans and non-Hispanic whites, a study reports. The study, “Ethnoracial differences in Alzheimer’s disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort,” was published in the journal Alzheimer’s &…
This post was originally published on this site Recently, researchers in England released preliminary findings from a twin study that suggests the development of nuclear cataracts may be significantly delayed if the patient eats a diet rich in vitamin C. The study, “Genetic and Dietary Factors Influencing the Progression of Nuclear Cataract,” was published in…
This post was originally published on this site Researchers have found that rural areas in Germany have lower standards of care offered to cataract patients compared to treatment received by those living in urban areas. “In this part of Germany there are only a few cities surrounded by countryside, where medical services are structurally weaker,” Tim Herbst,…
This post was originally published on this site Myopia, which affects the muscles used to focus the lens of the eye, appears to have clinical implications for “accommodating,” or focusing, intraocular lens (IOLs) implants that help the eye adapt to different visual distances, according to a study in the journal Optometry and Vision Science, titled “The Effect of Age,…
This post was originally published on this site Alcon, a Novartis sub-arm specializing in eye care, has announced it received European CE Mark for its AcrySof IQ Aspheric IOL with the UltraSert Pre-loaded Delivery System for patients undergoing cataract surgery. This approval comes right after Alcon’s CE Mark for its trifocal presbyopia-correcting AcrySof IOL, in June 2015. The new…
This post was originally published on this site Sterubin, an active chemical compound extracted from a native California plant, was found to hold neuroprotective and anti-inflammatory potential for Alzheimer’s disease, a study shows. The study, “Old age-associated phenotypic screening for Alzheimer’s disease drug candidates identifies sterubin as a potent neuroprotective compound from Yerba santa,” was…
This post was originally published on this site A Phase 1 clinical trial in healthy volunteers for investigational therapy AZP2006 — an oral medicine that is meant to clear accumulations of toxic proteins in Alzheimer’s disease and progressive supranuclear palsy — has shown positive results, says the therapy’s developer, AlzProtect. Progressive supranuclear palsy (PSP) is a rare, progressive disease…
This post was originally published on this site Denali Therapeutics has begun dosing patients in its Phase 1b clinical trial of DNL747 as a treatment for Alzheimer’s disease. “We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS [central nervous system] penetration, and target engagement, at the…
This post was originally published on this site A Phase 2 trial is enrolling patients with moderate Alzheimer’s to test an investigational antibody known as RO7105705 that targets the Tau protein. The Genentech-sponsored multicenter, randomized study (NCT03828747) intends to assess the efficacy, safety, and pharmacological profile of RO7105705. The company plans to recruit 260 patients…
